Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians by Raffaella Palumbo, Federico Sottotetti, Alberto Riccardi, Cristina Teragni, Emma Pozzi, Erica Quaquarini, Barbara Tagliaferri, Antonio Bernardo

Get full text

Health-related quality of life and clinical complexity of a real-life cohort of patients with advanced HR+/HER2– breast cancer treated with CDK4/6 inhibitors and endocrine therapy... by Barbara Tagliaferri, Ludovica Mollica, Raffella Palumbo, Claudia Leli, Alberto Malovini, Matteo Terzaghi, Erica Quaquarini, Cristina Teragni, Stefano Maccarone, Andrea Premoli, Federico Sottotetti

Get full text

Patterns of treatment and outcome with 500-mg fulvestrant in postmenopausal women with hormone receptor-positive/HER2-negative metastatic breast cancer: a real-life multicenter Ita... by Raffaella Palumbo, Federico Sottotetti, Erica Quaquarini, Anna Gambaro, Antonella Ferzi, Barbara Tagliaferri, Cristina Teragni, Luca Licata, Francesco Serra, Pietro Lapidari, Antonio Bernardo

Get full text

Nivolumab Induced Thyroid Dysfunction: Unusual Clinical Presentation and Challenging Diagnosis by Carmine Iadarola, Laura Croce, Laura Croce, Erica Quaquarini, Erica Quaquarini, Cristina Teragni, Sara Pinto, Antonio Bernardo, Rodolfo Fonte, Michele Marinò, Mario Rotondi, Luca Chiovato

Get full text

The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitors by Federico Sottotetti, Elisa Ferraris, Barbara Tagliaferri, Raffaella Palumbo, Erica Quaquarini, Cristina Teragni, Emanuela Balletti, Claudia Leli, Andrea Premoli, Ludovica Mollica, Silvia Puglisi, Silvia Sardi, Alberto Malovini, Paolo Pedrazzoli, Antonio Bernardo

Get full text